Not All Pills Are the Same Pill
Back to contraception, because “the pill” isn’t one thing and the differences matter more than most women are told.
The progestin decides a lot of it. Combined pills pair estrogen with one of several progestins, and they don’t carry equal risk. Pills using levonorgestrel — an older, second-generation progestin — consistently show the lowest clot risk of the combined options. Newer progestins like desogestrel, gestodene, and drospirenone carry roughly one and a half to two times the risk of levonorgestrel pills. Same category of drug. Different number.
The estrogen dose matters too. Lower-dose formulations carry less risk than higher-dose ones.
And then the option that resolves the question entirely: progestin-only methods carry essentially no increased clot risk at all. The mini-pill. The hormonal IUD. No estrogen, no liver signal, no extra clotting factors. For a woman who genuinely can’t take estrogen — a previous clot, Factor V Leiden, a smoker over 35 — these aren’t a consolation prize. They’re highly effective contraception without the mechanism that causes the problem.
Which is the pattern running through this entire article: the answer is almost never “stop.” It’s usually “switch.”
Cancer Treatment: A Different Conversation
ADVERTISEMENT
This one belongs on the list, but it deserves honest framing rather than a warning.
Certain treatments do raise clot risk — some chemotherapy agents, some newer targeted therapies, some hormonal treatments like tamoxifen. That’s real.
But the dominant factor usually isn’t the drug. It’s the cancer. Malignancy itself makes blood substantially more likely to clot — a link doctors have recognized for over 150 years. For many patients, the disease is a bigger clotting risk than anything used to treat it.
This matters because it inverts the logic. Refusing a treatment to avoid clots can mean keeping the thing that’s causing them.
Your oncology team already knows all of this. They assess clot risk formally, they monitor for it, and they prescribe preventive blood thinners when the risk is high enough to warrant it. If you’re in cancer treatment and worried about clots, that’s a conversation to have with the team managing it — not a reason to hesitate.
